Letrozole Sanoswiss

Letrozole, the active ingredient in Letrozole Sanoswiss, is an aromatase inhibitor presented as a tablet for oral use. It reduces estrogen production and is employed in the treatment of hormone‑receptor‑positive breast cancer in postmenopausal women. GNH USA supplies Letrozole Sanoswiss as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Letrozole is an aromatase inhibitor used in hormone‑dependent breast cancer therapy.

- Hormone receptor‑positive breast cancer in postmenopausal women: reduces estrogen levels to inhibit tumor growth. - Adjuvant treatment of early‑stage breast cancer: lowers the risk of disease recurrence after surgery. - Metastatic breast cancer: provides disease control in advanced, estrogen‑driven tumors.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching in joints or muscles. - Fatigue: persistent tiredness. - Nausea: feeling of queasiness. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Osteopenia or osteoporosis: decreased bone mineral density, increasing fracture risk. - Thromboembolic events: blood clots in veins or arteries. - Severe liver injury: marked elevation of liver enzymes or hepatitis. - Allergic reactions: rash, swelling, or anaphylaxis. - Cardiac arrhythmias: QT interval prolongation or other rhythm disturbances.

Letrozole requires careful monitoring and specific precautions.

- Bone health monitoring: assess bone mineral density regularly. - Cardiovascular assessment: evaluate risk factors for thrombosis and heart disease. - Liver function testing: check hepatic enzymes before and during therapy. - Pregnancy contraindication: avoid use in pregnant or breastfeeding women (Category X). - Drug interaction review: assess concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Letrozole may interact with several medicines, requiring vigilance.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce letrozole exposure. - Tamoxifen: antagonistic estrogen‑modulating effects can diminish therapeutic benefit. - Certain chemotherapy agents that share metabolic pathways may increase toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): letrozole can enhance anticoagulant effect, increasing bleeding risk. - SSRIs or SNRIs: may exacerbate hot‑flash symptoms. - Cholesterol‑lowering agents (e.g., statins): monitor for altered plasma levels.